Rasburicase (Elitek): a novel agent for tumor lysis syndrome

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• The incidence of tumor lysis syndrome (TLS) in adults remains poorly defined and unpredictable.
• While various prevention and treatment strategies exist, rasburicase represents a recent advancement.

Purpose of the Study:

• To review the role of rasburicase in managing tumor lysis syndrome and hyperuricemia.
• To discuss its efficacy, adverse effects, and practical considerations for use in adult patients.

Main Methods:

• Review of clinical trials and FDA-approved indications for rasburicase.
• Analysis of comparative data with traditional treatments like allopurinol and sodium bicarbonate.
• Examination of laboratory handling requirements during rasburicase therapy.

Main Results:

• Rasburicase, a recombinant urate oxidase, is FDA-approved for TLS risk and hyperuricemia, effective in pediatric and adult populations, though indicated only for pediatrics.
• Potential adverse effects include anaphylaxis and methemoglobinemia.
• Laboratory test accuracy for uric acid requires special handling procedures when patients are on rasburicase.

Conclusions:

• Rasburicase is an effective treatment for TLS and hyperuricemia but carries significant risks and costs.
• Judicious use is recommended, especially considering its higher price compared to allopurinol and sodium bicarbonate.
• Further research may clarify its optimal role in adult oncology care.